Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eye Of The Pricing Storm: FDA's Woodcock Withstands Gale-Force Rhetoric

Executive Summary

House committee members deliver a fierce, if not terribly substantive, critique of FDA review processes as part of a hearing on Turing and Valeant.

You may also be interested in...



Mylan's EpiPen Nightmare Not Over Yet, But Will Congress Just Write?

Unless Republicans are convinced the market can't fix the problem, Mylan officials may only get congressional letters on the EpiPen price increase.

Why Generic EpiPen Is Not The Answer – Until FDA Says It Is

There is no question that the concerns over Mylan’s price increases for EpiPen would deflate as rapidly as the price once an interchangeable generic is approved by FDA, but putting pressure on FDA to get a generic to market may be counterproductive.

At Drug Pricing Hearing, Innovator Companies Mainly Escape Congressional Wrath

Members of House Oversight Committee accuse Turing and Valeant of 'trashing' mainstream innovator companies with their drug pricing practices.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel